American Heart Journal
Volume 151, Issue 5 , Pages 976.e7-976.e11 , May 2006

Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers

Received 18 August 2005 ,Accepted 5 February 2006.

References 

  1. Steinhubl SR. Antiplatelet therapy: aspirin. J Invasive Cardiol. 2003;15(Suppl B):11B–16B
  2. Van Hecken A, Juliano ML, Depre M, et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment Pharmacol Ther. 2002;16:1683–1688
  3. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am. 2000;84:163–179
  4. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15–28
  5. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004;43:1127–1129
  6. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  7. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–2202
  8. Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin-induced gastric mucosal damage: prevention by enteric coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991;32:77–83
  9. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 1999;13:1109–1114
  10. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay—ASA. Am J Cardiol. 2003;92:1492–1494
  11. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122–1126
  12. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35:175–178
  13. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–1687
  14. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399–406
  15. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177–1184
  16. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655
  17. Gonzales-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals. Heterogeneous response or aspirin failure?. Stroke. 2005;36:276–280
  18. Cole AT, Hudson N, Liew LC, et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?. Aliment Pharmacol Ther. 1999;13:187–193
  19. Hawkey CJ, Hawthorne AB, Hudson N, et al. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach. Clin Sci (Lond). 1991;81:565–573
  20. Howe GB, Champion GD, Corrigan AB, et al. The effects of enteric coating of aspirin tablets on occult gastrointestinal blood loss. Aust N Z J Med. 1977;7:600–604
  21. Ridker PM, Hennekens CH, Tofler GH, et al. Antiplatelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk. 1996;3:209–212
  22. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148:263–268

☆ This study was funded by the Cleveland Clinic Foundation Research Programs Council and the Department of Cardiovascular Medicine. The VerifyNow assays were donated without charge by Accumetrics, Inc, San Diego, CA.

PII: S0002-8703(06)00140-2

doi: 10.1016/j.ahj.2006.02.017

American Heart Journal
Volume 151, Issue 5 , Pages 976.e7-976.e11 , May 2006

Article Tools

* Image Usage & Resolution